Skip to main content
Clinical Trials/CTRI/2025/01/079515
CTRI/2025/01/079515
Not yet recruiting
Phase 3

A randomised double arm parallel clinical study to compare the effectiveness of Urtica Urens mother tincture versus Individualised homoeopathic medicine in the management of Gout

Dr Nandini Maurya1 site in 1 country60 target enrollmentStarted: February 3, 2025Last updated:

Overview

Phase
Phase 3
Status
Not yet recruiting
Sponsor
Dr Nandini Maurya
Enrollment
60
Locations
1
Primary Endpoint
Gout Impact Scale

Overview

Brief Summary

The study will be a Prospective, Double Arm Parallel group, open label,

Randomized clinical study. Patients will be randomly allocated in 1:1 ratio by using

computerised Block Randomization into 2 groups: URTICA URENS MOTHER TINCTURE

treatment group and INDIVIDUALISED HOMOEOPATHIC MEDICINE treatment group.

Primary objective is to evaluate which is more effective i.e., URTICA URENS MOTHER TINCTURE or

INDIVIDUALISED HOMOEOPATHIC MEDICINE in management of Gout and; to assess the improvement of patient in terms of frequency of attack and severity of symptoms of Gout.

Duration of study is 1 year. Sample size is 60; 30 in each group.

Research Analysis

Assessment of clinical response/ outcome.

Relief from symptoms and suffering.

Assessment of improvement by using Gout Impact Scale and Pain Visual Analogue

Scale.

Laboratory investigations: Serum Uric Acid

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
30.00 Year(s) to 70.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Patients having sign and symptoms of Gout.
  • Pre diagnosed cases of Gout.
  • Patients who have not taken any treatment for gout in the last 2 weeks.
  • Patients with serum uric acid level over 7.0 mg/dl
  • Patients giving informed consent.
  • Patients willing to come for regular followups.

Exclusion Criteria

  • Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled systemic illness or life- threatening infections affecting quality of life or any vital organ failure.
  • Pregnancy, puerperium and lactation.
  • Substance abuse and/or dependence.
  • Self-reported immune-compromised state.
  • Patients who are already enrolled in some other study.
  • Patients who are not willing to give the consent.

Outcomes

Primary Outcomes

Gout Impact Scale

Time Frame: 1 month

Secondary Outcomes

  • Pain Visual Analogue Scale(1 month)
  • Serum Uric Acid Level(4 weeks)

Investigators

Sponsor
Dr Nandini Maurya
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Dr Nandini Maurya

Nehru Homoeopathic Medical College and Hospital

Study Sites (1)

Loading locations...

Similar Trials